Results 111 to 120 of about 91,755 (270)

Nivolumab-refractory patients with advanced non-small-cell lung cancer

open access: yes, 2019
International audienceIntroduction: Immune checkpoint inhibitors (ICIs) have revolutionised cancer care especially in lung cancer. New response patterns have been described under ICIs such as pseudo-progression or hyper-progressive disease (HPD).
Friard, S.   +25 more
core   +1 more source

A rare cause of dysphagia: A case report on gastroesophageal adenocarcinoma in childhood

open access: yesJPGN Reports, EarlyView.
Abstract Dysphagia is a common symptom in pediatric patients with a broad differential diagnosis, while gastroesophageal (GE) malignancies represent an exceptionally rare cause. We report a previously healthy 9‐year‐old female patient who presented with 1 month of progressive dysphagia, intractable vomiting, and weight loss.
Leo Fawaz   +2 more
wiley   +1 more source

When Explant Surprises: Management and Outcomes of Hepatocellular Carcinoma Beyond Milan Criteria Discovered Post‐Transplant‐ A Narrative Review of Literature

open access: yesJournal of Surgical Oncology, EarlyView.
ABSTRACT Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan.
Serkan Sucu   +2 more
wiley   +1 more source

Alopecia Areata in a Patient Receiving Cemiplimab for Metastatic Cutaneous Squamous Cell Carcinoma

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Alopecia areata (AA) is an autoimmune disease characterized by non‐scarring hair loss of the scalp and/or body, with an unpredictable and variable clinical course. Its etiology is not entirely understood, although evidence suggests that environmental, immunological, and genetic factors contribute to disease development.
Marco Rubatto   +7 more
wiley   +1 more source

Diabetes Mellitus Induced by Nivolumab plus Regorafenib in a Patient with Esophageal Cancer

open access: yesJournal of Cancer Research and Practice
Nivolumab is now preferred as first-line and second-line treatment for advanced esophageal cancer, while regorafenib improves survival in refractory gastroesophageal cancer.
Mei-Chen Lin   +4 more
doaj   +1 more source

Cutaneous Eruptions Associated With Tumour Infiltrating Lymphocyte Therapy: A Case Series

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Tumour‐infiltrating lymphocyte (TIL) therapy is a newly emerged effective treatment for advanced melanoma refractory to immune checkpoint inhibitors; however, its cutaneous adverse effects remain uncharacterized. We present the first case series describing dermatologic adverse effects associated with TIL therapy for malignant melanoma in five ...
Shannon C. Lyden   +9 more
wiley   +1 more source

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

open access: yes
Nivolumab for Resected Stage III or IV Melanoma at 9 Years (Original Article, N Engl J Med 2026;394:333-342). In Figure 1B (page 338), the number at risk in the nivolumab group at month 48 should have been 202, rather than 212.
Márquez‐Rodas, Iván   +28 more
core   +1 more source

Nivolumab for the treatment of unresectable pleural mesothelioma

open access: yes, 2019
Introduction: Platinum-based chemotherapy is the current first-line standard therapy for unresectable malignant pleural mesothelioma (MPM). Recently, immune-checkpoint inhibitors (ICI) have been intensively investigated as treatment options for this ...
Nobukazu Fujimoto (81969)   +4 more
core   +1 more source

Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT The prognostic nutritional index (PNI) and geriatric nutritional risk index (GNRI) are simple markers that reflect immune and nutritional status. This retrospective study evaluated their prognostic significance in 276 patients with advanced hepatocellular carcinoma (HCC) who received first‐line lenvatinib. PNI and GNRI were calculated based on
Cheng‐Wei Kuo   +9 more
wiley   +1 more source

Composite Inflammatory Score for Predicting Progression‐Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First‐Line Toripalimab Plus Axitinib

open access: yesThe Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Routine inflammatory and nutritional markers may help stratify progression risk in metastatic clear cell renal cell carcinoma during immunotherapy‐based treatment. This single‐center retrospective study included 237 patients who received first‐line toripalimab plus axitinib therapy.
Yun‐Feng Wu   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy